Orchestra BioMed Holdings Past Earnings Performance
Past criteria checks 0/6
Orchestra BioMed Holdings's earnings have been declining at an average annual rate of -29.3%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 59.6% per year.
Key information
-29.3%
Earnings growth rate
71.6%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 59.6% |
| Return on equity | -124.8% |
| Net Margin | -2,179.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Orchestra BioMed Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3 | -58 | 22 | 40 |
| 30 Jun 24 | 2 | -56 | 23 | 37 |
| 31 Mar 24 | 2 | -52 | 22 | 35 |
| 31 Dec 23 | 3 | -49 | 20 | 34 |
| 30 Sep 23 | 4 | -46 | 19 | 33 |
| 30 Jun 23 | 4 | -43 | 18 | 30 |
| 31 Mar 23 | 4 | -39 | 16 | 27 |
| 31 Dec 22 | 4 | -34 | 14 | 22 |
| 30 Sep 22 | 0 | -32 | 13 | 18 |
| 30 Jun 22 | 0 | -27 | 9 | 16 |
| 31 Mar 22 | -1 | -25 | 8 | 13 |
| 31 Dec 21 | -1 | -23 | 8 | 13 |
| 31 Dec 20 | 6 | -21 | 11 | 13 |
Quality Earnings: OBIO is currently unprofitable.
Growing Profit Margin: OBIO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OBIO is unprofitable, and losses have increased over the past 5 years at a rate of 29.3% per year.
Accelerating Growth: Unable to compare OBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OBIO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.4%).
Return on Equity
High ROE: OBIO has a negative Return on Equity (-124.81%), as it is currently unprofitable.